1don MSN
Clinical trial of personalized cancer vaccine demonstrates feasibility, safety, immune activation
The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...
News-Medical.Net on MSN
Immune checkpoint inhibitors can trigger rare immune thrombocytopenia in cancer patients
Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale ...
HealthDay on MSN
Timing of Immune Checkpoint Inhibitor Administration Affects Small Cell Lung Cancer Survival
Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival.
Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more ...
IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, Dec. 4 ...
News Medical on MSN
JMC Publication: Insilico’s AI platforms enable discovery of potent, selective, oral DGKα inhibitor to overcome checkpoint resistance
Novel, Potent, Selective and Orally Available DGKα Inhibitors for the Treatment of Tumors view more . Credit: Insilico ...
Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...
Based on the response data, coupled with the supportive IFN- <GAMMA> biomarker data, Pliant plans to accelerate the development of PLN-101095 with the initiation of a Phase 1b indication expansion ...
In a recent preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback